Status:
COMPLETED
Ketorolac-an Option for Post Operative Pain Management After Elective Cardiac Surgery.
Lead Sponsor:
National Institute of Cardiovascular Diseases, Pakistan
Conditions:
Coronary Artery Disease
Post Operative Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
OBJECTIVE: The purpose of this study was to compare the efficacy of Ketorolac versus Paracetamol as an adjunct to Nalbuphine in the management of post-operative pain following elective cardiac surgery...
Detailed Description
DATA COLLECTION: Computer randomization was done for the numbers 1 to 60, having 50% probability of being in either of two groups: Ketorolac (treatment) or Paracetamol (control). After randomizing ea...
Eligibility Criteria
Inclusion
- Males and females between 18 years and above of age.
- Undergoing elective cardiac surgery.
- American Society of Anesthesiology (ASA) Physical Class 3 or 4.
Exclusion
- • Patients pre-planned for delayed extubation (due to moderate to severe pulmonary artery hypertension, poor right ventricular function, rhythm disturbances or unstable vitals)
- Low cardiac output (cardiac index \< 2.0 l/min/m2, using transesophageal echocardiography, intraoperatively) after weaning off cardiopulmonary bypass or paitients already having pre-op ejection fraction \< 30%.
- Patients not comfortably ventilated or oxygenated, requiring high doses of sedation and neuromuscular blockage.
- Sensitivity or allergy to nonsteroidal anti-inflammatory drugs.
- History of peptic ulcer or gastrointestinal bleeding.
- Serum creatinine = 2.0 mg/dl or increase in serum creatinine of = 0.5 mg/dl or 25% within the preceding 10 days.
- Hepatic dysfunction.
- Bleeding disorder.
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 6 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05361824
Start Date
January 1 2021
End Date
July 6 2021
Last Update
September 30 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Cardiovascular Diseases
Karachi, Sindh, Pakistan